San Diego respiratory devices maker ResMed (NYSE:RMD) filed a new complaint with the International Trade Commission, this time against Chinese medtech company BMC Medical Co. and its U.S. subsidiary 3B Products.
ResMed Inc.
ResMed infringement claim against Apex Medical ends with a question mark
Legal: ResMed pounces on another potential patent violator
FDA clears ResMed’s at-home respiratory assist device
Federal regulators cleared ResMed‘s (NYSE:RMD) variable positive airway pressure device for at-home use for patients with chronic obstructive pulmonary disease.
The VPAP device, used at night to prevent acute respiratory exacerbations, was built on San Diego-based ResMed’s S9 platform, according to a press release.
ResMed takes aim at APEX Medical over respiratory device patents
ResMed CEO Farrell hands corner office to his son | Personnel Moves
ResMed slides despite record Q2 sales and profits
ResMed (NYSE:RMD) shares fell nearly 7% this morning after the medical device company posted record sales and profits for its fiscal 2nd quarter, but missed Wall Street’s earnings expectations.
The San Diego-based medical device company posted profits of $77.9 million, or 53¢ per share, on sales of $376.5 million for the 3 months ended Dec. 31, 2012.
Medical Device Companies: Medtech’s best/worst valued stocks
One way to assess stock values is to compare the stock’s share price with its asset value.
The latter is the number of shares outstanding divided into total assets. When the result is compared with share prices, it can help investors decide whether a stock is over- or under-valued.
We took a look at the asset values for 15 of the world’s largest pure-play medical device companies and then compared them with the companies’ stock price.
ResMed to add 50 Ireland jobs for high-target medtech development project
Sleep and respiratory devices maker ResMed (NYSE:RMD) is planning a large-scale research, development and innovation project at its Ireland facility, expecting to add 50 new jobs over the next 3 years.
The company is working on non-contact sensors to help chronic disease patients manage their condition at home, according to Ireland government reports.
Thoratec kills it in Q1, Wall Street shrugs | Earnings Roundup
Thoratec (NSDQ:THOR) started today up 7.2% as investors reacted to its stellar 1st-quarter numbers, but by the time the market closed THOR shares had fallen back to Earth to close at $34.46, down 0.1%.
The heart pump maker posted profits of $25.5 million, or 43¢ per diluted share, on sales of $126.8 million for the 3 months ended March 31.
Venture capital outlook a mixed bag | Wall Street Beat
The volatility of the stock markets last year was mirrored in the venture capital arena, according to Mark Heesen, president of the National Venture Capital Assn.
"Be prepared for a roller coaster ride here, because that’s where we’ve been for the past year – and that’s where we’re going," Heesen told Xconomy.